Clinical trials
Autoimmunity clinical trials
Below are recruiting autoimmunity clinical trials, each written for real people, not researchers. We’re tracking 341 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07085104RecruitingPhase 1
Study of ALLO-329 for lupus, myositis, or scleroderma
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
Phoenix, ArizonaAges 18–74 - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT06980597RecruitingPhase 1
Testing OL-108 for active autoimmune diseases
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
BeijingAges 18–65 - NCT07038447Enrolling by invitationPhase 1
A study of KITE-363 for people with severe autoimmune diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune diseases (like lupus, scleroderma, or inflammatory myositis) that haven't improved with standard treatments. The goal is to see if KITE-363 can reduce disease activity and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT07040774Recruiting
Study of type 1 interferonopathies in Europe
This study looks at people with a confirmed type 1 interferonopathy, a rare immune condition caused by a gene change. It aims to learn more about how the condition progresses over time.
InnsbruckAges Any age - NCT07021209RecruitingPhase 1
GT719 for returning or hard-to-treat autoimmune neurological diseases
This trial tests a new antibody drug (GT719) for adults with autoimmune neurological diseases that came back or did not get better with standard treatment. It looks at how safe the drug is and how well it works.
Wuhan, HubeiAges 18–75 - NCT07015580Recruiting
Mouth bacteria in pancreatitis types
This study looks at the bacteria in your mouth to see if they are different in chronic pancreatitis and autoimmune pancreatitis. It might help doctors understand these diseases better.
Shanghai, Shanghai, ChinaAges 18 years+ - NCT06797024Recruiting
Study of JY231 injection for tough nerve immune disorders
This trial tests a new injection called JY231 for people with certain hard-to-treat nerve and immune disorders that haven't improved with standard treatments. It aims to see if this experimental therapy can help control the disease when other options have failed.
Wuhan, HubeiAges 18–75 - NCT07011147Recruiting
Real-world test of automated insulin delivery in primary care
This study tests if an automated insulin delivery system (the iLet bionic pancreas) works well in real-world primary care settings for people with type 1 or type 2 diabetes. It aims to see if this technology can help manage blood sugar more easily.
Aurora, ColoradoAges 18–89 - NCT06978647RecruitingPhase 1
YTS109 cell therapy for stubborn autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT06967701Recruiting
Building exercise habits for type 1 diabetes
This study helps adults with type 1 diabetes who don't exercise much build a safe and lasting exercise routine. You'll learn how to start moving more while managing your insulin and blood sugar levels.
New Haven, ConnecticutAges 30–65 - NCT06947460RecruitingPhase 1/Phase 2
CAR-T cell therapy for resistant lupus, sclerosis, and Sjögren's lung disease
This trial tests a special immune cell therapy (CAR-T cells targeting CD19 and BCMA) for people with lupus nephritis, systemic sclerosis, or Sjögren's-related lung blood vessel disease that hasn't improved with usual treatments. The goal is to see if this one-time cell infusion can calm the overactive immune system and improve symptoms.
Beijing, China,BeijingAges 10–65 - NCT06940869Enrolling by invitation
Reproductive health registry for rheumatic conditions
This study creates a registry to better understand pregnancy outcomes in people with autoimmune or rheumatic conditions. If you are aged 12 to 55, can become pregnant (or are currently pregnant or planning a pregnancy), and receive care at Duke Health, you may be eligible to join.
Durham, North CarolinaAges 12–55 - NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
La Jolla, CaliforniaAges 18–70 - NCT06888973Enrolling by invitationPhase 1/Phase 2
Stem cell infusion for autoimmune diseases
This clinical trial is testing if infusions of special stem cells (called mesenchymal stem cells) can help people with certain autoimmune diseases where standard treatments have not worked well enough. It is an early-phase study in Pakistan for adults (and some children for one condition) with rheumatoid arthritis, lupus, systemic sclerosis, ankylosing spondylitis, or dermatomyositis/polymyositis.
RawalpindiAges 18–50 - NCT04372615RecruitingPhase 2
Inebilizumab for NMDA receptor encephalitis after initial steroids
This Phase 2 study tests inebilizumab in people with NMDA receptor encephalitis, an immune-related brain condition. It looks to see if adding this treatment after starting steroids (and possibly other first treatments) improves recovery and safety.
Birmingham, AlabamaAges 12 years+ - NCT06863974Recruiting
Finding markers of relapsing nerve inflammation in children
This study looks at children who have had a first attack of nerve inflammation (like ADEM, vision loss, or spinal cord issues) to find markers in the blood that might show if it will come back. It tests blood and cells to better understand the immune response.
AngersAges 18 years+ - NCT06867991RecruitingPhase 3
Combination therapy for autoimmune encephalitis
This study tests if combining two medications (a B-cell depleting drug and daratumumab) can help people with autoimmune encephalitis who haven't improved with standard treatments.
Zhengzhou, HenanAges 12 years+ - NCT06866652Recruiting
Why Am I Short of Breath? A Study in Myasthenia Gravis
This study looks at why people with myasthenia gravis (MG) feel short of breath. It aims to understand breathing problems that happen in daily life, even when MG seems stable.
ParisAges 18 years+ - NCT06826430RecruitingPhase 1
CAR-T cell therapy for severe lupus-related low platelets
This trial tests a new CAR-T cell treatment called Inaticabtagene Autoleucel for people with lupus that causes very low platelet counts (immune thrombocytopenia) that hasn't gotten better with standard treatments. The goal is to see if it can help raise platelet levels.
Beijing, Beijing MunicipalityAges 18–70 - NCT06828042RecruitingPhase 1/Phase 2
CAR-γδT cells for refractory autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
BeijingAges 18–80 - NCT06817889RecruitingPhase 2
Remdesivir for RSV in people with weak immune systems
This trial tests if remdesivir can safely treat RSV (a respiratory virus) in people with weakened immune systems, such as those who have had a stem cell or bone marrow transplant, CAR T-cell therapy, or are being treated for blood cancer. If you have a confirmed RSV infection in your nose or throat and are at moderate or high risk for complications, you may be able to join.
Duarte, CaliforniaAges 18 years+ - NCT06811935Recruiting
PEDI Study for Kids with PANS or PANDAS
This study looks at children who may have PANS or PANDAS, conditions that can cause sudden changes in behavior or mood after an infection. It aims to better understand these conditions and improve care.
Lebanon, New HampshireAges 3–17
Hear when a new Autoimmunity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autoimmunity?
- Yes. Clin2 currently lists 341 recruiting autoimmunity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autoimmunity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autoimmunity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.